RxDoctor Payments DataLook up a doctor →

Angel Herrera, MD

Geriatric Medicine · Naples, FLNPI 1316986680

Payments from drug & device makers

$12,255in general payments, 2019–2025

Across 671 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Boehringer Ingelheim$838
  • Novartis$755
  • Merck$614
  • plus $6K from 46 others

What the payments were for

  • Food & beverage$12,09999%
  • Education$1571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,255 in reported general payments places this provider in the 95th percentile of 305 geriatric medicine providers in Florida.

See all geriatric medicine providers in Florida

Medicare billing

Part B allowed, 2024
$228,456
Medicare patients
346
Services billed
5,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$198,506
OzempicSemaglutide111$181,419
FarxigaDapagliflozin Propanediol89$129,027
JardianceEmpagliflozin67$82,499
RybelsusSemaglutide27$63,973
GlyxambiEmpagliflozin/Linagliptin49$62,406
TrulicityDulaglutide24$42,128
MounjaroTirzepatide25$36,293
XareltoRivaroxaban21$33,339
VascepaIcosapent Ethyl53$29,766
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$27,729
Trijardy XrEmpaglifloz/Linaglip/Metformin17$18,407
Tresiba Flextouch U-100Insulin Degludec25$17,947
Repatha SureclickEvolocumab18$15,612
Rosuvastatin Calcium590$7,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,351$245,393138 claims
PfizerEliquis$1,164$198,506128 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr$838$163,312133 claims
AstraZenecaFarxiga$384$129,02789 claims
Lilly USA, LLCTrulicity, Mounjaro$569$78,42149 claims
Johnson & JohnsonXarelto$317$33,33921 claims
GSKTrelegy Ellipta$493$27,72924 claims
Arbor Pharmaceuticals, Inc.Edarbi$14$5,92615 claims
AbbVieSynthroid$208$1,32620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 geriatric medicine providers in Florida.

Other geriatric medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →